News

Filter

Current filters:

ImbruvicaPharmacyclics

1 to 9 of 15 results

Janssen and Pharmacyclics submit EMA application to expand indication for Imbruvica

Janssen and Pharmacyclics submit EMA application to expand indication for Imbruvica

01-12-2014

US health care giant Johnson & Johnson’s Belgium-based subsidiary Janssen-Cilag International has submitted…

EuropeImbruvicaJanssen-CilagOncologyPharmaceuticalPharmacyclicsRegulation

AstraZeneca, Pharmacyclics and Janssen team up on Imbruvica and MEDI4736 combination trial

AstraZeneca, Pharmacyclics and Janssen team up on Imbruvica and MEDI4736 combination trial

04-11-2014

Anglo-Swedish drug major AstraZeneca and US health care giant Johnson & Johnson’s Europe-based subsidiary…

AstraZenecaBiotechnologyImbruvicaJanssenMEDI4736OncologyPharmacyclicsResearchUK

Non-Hodgkin lymphoma market to grow to $9.2 billion

Non-Hodgkin lymphoma market to grow to $9.2 billion

29-10-2014

The non-Hodgkin lymphoma (NHL) market will be worth $9.2 billion by 2020, according to new research.

Celgene Corp.EuropeGilead SciencesImbruvicaJanssen BiotechJohnson & JohnsonMabTheraOncologyPharmaceuticalPharmacyclicsResearchRevlimidRocheUSAVelcadeZydelig

Pharmacyclics files Imbruvica sNDA for Waldenstrom’s macroglobulinemia

20-10-2014

US drugmaker Pharmacyclics has submitted a supplemental New Drug Application to the US Food and Drug…

ImbruvicaJanssen BiotechJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulationUSA

Pharmacyclics’ Imbruvica gains EU approval for two blood cancers

17-10-2014

US drugmaker Pharmacyclics has received marketing approval from the European Commission for Imbruvica…

EuropeImbruvicaJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulation

Pharmacyclics and Roche research Imbruvica and Gazyva

Pharmacyclics and Roche research Imbruvica and Gazyva

17-10-2014

USA-based biopharma company Pharmacyclics has entered into a master clinical drug supply agreement with…

GazyvaImbruvicaOncologyPharmaceuticalPharmacyclicsResearchRocheUSA

Bristol-Myers Squibb, Pharmacyclics and Janssen team up to test Opdivo and Imbruvica combination

Bristol-Myers Squibb, Pharmacyclics and Janssen team up to test Opdivo and Imbruvica combination

13-10-2014

US drug major Bristol-Myers Squibb, US-based biopharma company Pharmacyclics and Janssen Research and…

BiotechnologyBristol-Myers SquibbEuropeImbruvicaJanssenOncologyOpdivoPharmacyclics

US FDA grants approval for Imbruvica for chronic lymphocytic leukemia

US FDA grants approval for Imbruvica for chronic lymphocytic leukemia

29-07-2014

The US Food and Drug Administration has granted USA-based Pharmacyclics approval for Imbruvica (ibrutinib)…

B-cell chronic lymphocytic leukemiaChronic lymphocytic leukemiaDanelle JamesImbruvicaJanssen BiotechOncologyPharmaceuticalPharmacyclicsRegulationUSA

1 to 9 of 15 results

COMPANY SPOTLIGHT

Menarini

Back to top